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Background: Socioeconomic status (SES) is independently associated with chronic kidney disease (CKD)
progression; however, its association with other CKD outcomes is unclear. In particular, the potential differential
effect of SES on mortality among blacks and whites is understudied in CKD. We aimed to examine survival among
individuals with prevalent CKD by income and race in the Reasons for Geographic and Racial Differences in Stroke
(REGARDS) study.
Methods: We examined 2,761 participants with prevalent CKD stage 3 or 4 between 2003 and 2007 in the
REGARDS cohort. Participants were followed through March 2013. Mortality from any cause was assessed by
income and race (black or white). Low income was defined as an annual household income < $20,000, and was
compared to higher incomes (≥$20,000). Cox proportional hazards models adjusted for age, gender, education,
insurance, CKD stage, comorbidity and county-level poverty were used to estimate hazard ratios (HR) and 95%
confidence intervals (CI).
Results: A total of 750 deaths (27.5%) occurred during the follow-up period. Average follow-up time was 6.6 years
among those alive and 3.7 years among those who died. Low income participants had an elevated adjusted hazard
of mortality (HR = 1.58, 95% CI 1.24-2.00) compared to higher income participants. Low income was associated with
all-cause mortality regardless of race (HR 1.53; 95% CI 1.18-1.99 among blacks and HR 1.38; 95% CI 1.10-1.74 among
whites), with no significant statistical interaction between household income and race (p-value = 0.634). However,
black participants had a higher adjusted hazard of mortality (HR = 1.30, 95% CI 1.02-1.65) compared to whites, which
was independent of income.
Conclusion: Income was associated with increased mortality for both blacks and whites with CKD. Blacks with CKD
had higher mortality than whites even after adjusting for important socio-demographic and clinical factors.Background
Approximately 14% of adults in the United States have
chronic kidney disease (CKD) and have a 60% increased
risk of mortality compared to those without CKD [1].
Blacks in the United States have a higher prevalence of ad-
vanced CKD and also progress more quickly to end-stage
renal disease (ESRD) than whites [2-4]. Several studies
have noted a “dialysis survival paradox” where blacks with
ESRD undergoing dialysis have better survival compared
to whites, despite having generally worse chronic disease* Correspondence: sfedewa@emory.edu
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unless otherwise stated.outcomes [5-10]. Though the reasons for this paradox are
not fully known, it is thought to be in part related to selec-
tion advantage of blacks who tend to develop ESRD at
younger ages [6]. Some studies suggest lower ESRD mor-
tality among blacks is due to higher mortality rates at earl-
ier stages of CKD; and thus those who survive to progress
to ESRD may be more robust [11,12]. Other studies sug-
gest the contrary [6,13-15].
SES is independently associated with CKD prevalence
[2] and progression [16]. However, the role of SES on
mortality among persons with CKD has received little at-
tention. Furthermore, the potential differential effect of
SES on mortality by race/ethnicity is also understudied,
though several SES and race interactions have been notedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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potential differential effect on mortality for blacks and
whites, we examined the association between household
income and survival by race among participants with
CKD in the Reasons for Geographic and Racial Differ-
ences in Stroke (REGARDS) study. We hypothesized that
lower income would be associated with lower all-cause
survival among individuals with CKD, and this association
would vary by race.
Methods
Study participants and data
The REGARDS study is a population-based national co-
hort of 30,239 non-institutionalized men and women aged
45 years and older, with almost equal numbers of blacks
and whites [20]. Approximately 20% of participants reside
in the Stroke Buckle (coastal plains of North Carolina
(NC), Georgia (GA) and South Carolina(SC)), 30% reside
in the Stroke Belt (remainder of NC, GA, SC, Mississippi,
Alabama, Louisiana, Arkansas and Tennessee) and 50% res-
ide in the other 42 contiguous United States.
Briefly, between January 2003 and October 2007, par-
ticipants completed a telephone interview and in-home
examination. Written consent was obtained from each
participant. Socio-demographic, household income, and
comorbidity data were ascertained through the telephone
interview. During an in-home visit, weight and height was
collected. Additionally, blood was collected for glucose
and serum creatinine measurement. Serum creatinine as-
says were calibrated to a creatinine standard determined
by isotope mass spectrometry [2]. Glomerular filtration
rate (GFR) was estimated using the CKD-EPI equation
based on a single serum creatinine measurement, which
we assumed reflected chronic kidney function [21]. Indi-
viduals with an estimated GFR (eGFR) <60 ml/min/
1.73 m2 were considered to have chronic kidney disease.
Individuals with CKD stage 5 at baseline, defined as eGFR
<15 ml/min per 1.73 m2,were excluded from our analysis.
Though participants with prevalent ESRD were excluded
at baseline, we examined incident ESRD in addition to
mortality as an outcome in our study to account for CKD
progression. REGARDS data were linked to the United
States Renal Data System (USRDS), which is a national
registry of patients with ESRD [22], to identify incident
ESRD.
Of the 30,239 REGARDS participants at baseline, 56
participants were excluded for missing data on several
key covariates, 25,529 did not have CKD at baseline, and
1,305 were missing data on eGFR. We excluded 167 par-
ticipants with CKD stage 5 or ESRD at baseline based
on REGARDS baseline eGFR and USRDS data. Add-
itionally, 3 participants were excluded due to a death
date prior to incident ESRD. Participants with missing
household income (n = 445) were excluded leaving 2,761individuals available for analysis. The REGARDS study
was approved by the Institutional Review Boards of the
sites involved.
Outcome
Mortality from any cause was our primary outcome of
interest and was assessed through telephone follow-up
every 6 months with a proxy that was identified by the
participant at baseline [20]. The National Death Index,
Social Security Death Index and death certificates were
used to identify death events for proxies who could not
be found and to confirm the date of death among those
reported dead by proxies. We also considered a com-
bined outcome of incident ESRD or mortality. Follow-up
data for our study was available through March 2013.
Primary predictors
Race was self-reported as black or white during the tele-
phone interview. Household income was used as the
primary measure of SES and was based on self-reported
annual income categories (<$20,000, $20,000-$34,999,
$35,000-$75,000 and > $75,000). Low income was de-
fined as < $20,000 based on its proximity to the federal
poverty threshold for a family of four ($19,350) in 2005.
Medium/high income was defined as ≥ $20,000 [23]. A
supplementary analysis using all four income categories
was conducted.
Covariates
Area-based measures including poverty and the Gini
Index, were also considered as neighborhood poverty may
contribute to kidney disease disparities [24]. County-level
Gini Index is a measure of wealth segregation [24,25].
Both Gini Index and county poverty data were based on
the 2000 U.S. Census [23]. Education was categorized as
no high school diploma, high school diploma, some col-
lege and college graduate. Having health insurance was
also considered as a covariate. Additional factors included
smoking status, grouped as former, current and never
smoker. Body mass index (BMI), measured in kg/m2, was
categorized as underweight (<18.5), normal weight (18.5
to 24.9), overweight (25 to 30) and obese (>30). Stage of
CKD, based on National Kidney Foundation Kidney Dis-
ease Outcomes Quality Initiative’s staging guidelines; were
classified as Stage 3 [eGFRs 30–59 (mL/min/1.73 m2)]
and Stage 4 [15–29 (mL/min/1.73 m2)] [26]. Diabetes was
defined based on self-reported medication use, fasting glu-
cose of ≥126 mg/dl or non-fasting glucose ≥ 200 mg/dl.
Presence of hypertension was determined by self-reported
use of anti-hypertensive medication, systolic blood pres-
sure ≥140 mm Hg or diastolic blood pressure ≥90 mm
Hg. Heart disease was based on self-reported history of
myocardial infarction, heart attack, or receipt of coronary
artery bypass grafting, angioplasty or stenting. Baseline
Fedewa et al. BMC Nephrology 2014, 15:136 Page 3 of 9
http://www.biomedcentral.com/1471-2369/15/136systolic and diastolic blood pressure was measured twice
in the left arm with a standard aneroid sphygmomanom-
eter after participants were seated in a chair for three mi-
nutes with both feet on the floor. The two blood pressure
measurements were averaged [20]. Baseline serum albu-
minuria (g/dL) was considered as a continuous variable.
Statistical analysis
Participant characteristics were examined by dichoto-
mized income and race using chi-square and t-test sta-
tistics (α = 0.05). Two outcomes 1) mortality as well as
2) mortality or incident ESRD was considered. Kaplan
Meier curves were used to estimate the proportion of
participants who died or developed ESRD over the study
period. Log-rank test statistics were used to determine
significant differences in survival. Cox proportional haz-
ards models were used to estimate unadjusted and ad-
justed hazard ratios (HR) and 95% confidence intervals.
Adjusted models included household income, race, age,
gender, education, geographic location, smoking status,
BMI, presence of hypertension, diabetes, heart disease,
systolic and diastolic blood pressure, serum albuminuria,
county Gini Index and county poverty. The Cox propor-
tional hazards assumption was examined by Schoenfeld
residuals. No gross violations in proportionality were de-
tected. Cox models stratified by race were conducted to
examine potential differential association of income with
mortality. Interaction between race and income was in-
vestigated. We also performed sensitivity analyses exam-
ining factors related to missing eGFR. All statistical
analyses were performed using SAS 9.3 (Cary, NC).
Results
Patient characteristics by income and race
The average age of participants was 70.9 years (+/− 9.1),
1,009 (36.5%) participants were black and 745 (27.0%)
reported low income. There were a higher proportion of
females, non-high school graduates and current smokers
in the low income group, and these persons were also
slightly older (Table 1). Low income participants had
higher prevalence of CKD stage 4, diabetes and hyper-
tension than those of higher income. Black participants
were slightly younger (mean age of 69.9 years) compared
to whites (mean age 71.5). Furthermore, there were a dis-
proportionate percentage of females and higher preva-
lence of obesity, CKD stage 4, diabetes, and hypertension
among blacks (Table 1).
Mortality by income level and other SES factors
A total of 750 deaths (27.5%) occurred during follow-up.
Average follow-up time was 79.0 months (+/− 24.5)
among those living and 44.5 months (+/− 25.0) among
those who died. Estimated survival was 52.9% and 71.8%
for black participants with low and higher incomes(p-value <0.001), respectively (Figure 1). Estimated sur-
vival was 61.4% and 65.3% for white participants with
low and higher incomes (p-value <0.001), respectively
(Figure 1). Participants with low income had a 58% in-
creased hazard of death in unadjusted analyses (Table 2).
In fully adjusted models accounting for demographics,
CKD stage, blood pressure, albuminuria, comorbidity
and county-level SES, hazard of mortality among low
income persons was attenuated, but remained statisti-
cally significant (HR = 1.58, 95% CI 1.24-2.00). Hazard
ratios for low income were attenuated when ESRD or
mortality was considered as the outcome, but remained
statistically significant (Table 3). When household in-
come was categorized into four groups participants
whose household income was < $20,000 (HR = 1.83, 95%
CI 1.31-2.55) had significantly higher adjusted hazards
of mortality compared to the highest household income
group (>$75,000). However, participants in the medium
income groups did not have elevated hazards of mor-
tality compared to the highest income group ($20,000
to $34,000, HR = 1.36, 95% CI 0.99-1.87 and $35,000 to
$74, 999, HR = 1.14, 95% CI 0.83-1.58). Residing in
counties with 16-20% poverty (HR = 1.40, 95% CI 1.12-
1.77) and counties with >20% poverty (HR = 1.33, 95% CI
1.03-1.70) was associated with significantly higher hazards
of mortality relative to counties with the lowest propor-
tion of poverty in adjusted models. Gini index, education,
and insurance were not significantly associated with mor-
tality in adjusted models.
Mortality by race
Unadjusted survival for blacks was higher than whites
among those with medium or high income; however, the
opposite was true for low income where blacks had worse
survival as shown in Figure 1. However, a test for inter-
action for race and income was not statistically significant
(p = 0.149). Black participants had a higher, but not statis-
tically significant, unadjusted hazard of mortality com-
pared to whites (HR = 1.15, 95% CI 0.99-1.33). The fully
adjusted HR for blacks was significantly higher compared
to whites (HR = 1.30, 95% CI 1.02-1.65) (Table 3). When
ESRD and mortality were considered as a composite out-
come, there was a strong association between black race
and ESRD or mortality. In unadjusted analyses black par-
ticipants had a 1.45 (95% CI 1.27-1.66) hazard of ESRD or
mortality compared to whites (Table 3) and this remained
significant following adjustment for other factors [HR 1.63
(95% CI 1.31-2.01)].
Mortality by income level stratified by race
Low income was associated with an 82% increase in HR
for mortality for blacks and a 38% increase for whites in
unadjusted models (Table 4). In adjusted models, low in-
come corresponded with a 59% and 34% increase in HR
Table 1 Individual and area level characteristics by individual level income and race, n = 2,761a
Total N (%) Low income N (%) Medium/high
income N (%)
P-valueb Black N (%) White N (%) P-valuec
Death 750 (27.54) 493 (24.76) 257 (35.11) < 0.0001 465 (26.72) 285 (28.99)
ESRD 204 (7.39) 141 (6.99) 63 (8.46) 0.19 65 (3.71) 139 (13.78)
Death or ESRD 873 (31.62) 580 (28.77) 293 (39.33) < 0.0001 499 (28.48) 374 (37.07)
Black Race 1009 (36.54) 622 (30.85) 387 (51.95) < 0.0001
No Insurance 100 (3.62) 53 (2.63) 47 (6.32) < 0.0001 39 (2.23) 61 (6.05) < 0.0001
Education < 0.0001 < 0.0001
<High School 468 (16.97) 190 (9.44) 278 (37.32) 191 (10.91) 277 (27.48)
HS Graduate 757 (27.45) 507 (25.19) 250 (33.56) 489 (27.94) 268 (26.59)
Some College 697 (25.27) 531 (26.38) 166 (22.28) 466 (26.63) 231 (22.92)
College Graduate 836 (30.31) 785 (39) 51 (6.85) 604 (34.51) 232 (23.02)
Age (years) 0.011 0.0002
<60 329 (11.92) 262 (13) 67 (8.99) 189 (10.79) 140 (13.88)
60-69 866 (31.37) 642 (31.85) 224 (30.07) 519 (29.62) 347 (34.39)
70-79 1028 (37.23) 729 (36.16) 299 (40.13) 671 (38.3) 357 (35.38)
≥80 538 (19.49) 383 (19) 155 (20.81) 373 (21.29) 165 (16.35)
Female 1530 (55.41) 998 (49.5) 532 (71.41) < 0.0001 890 (50.8) 640 (63.43) < 0.0001
Region < 0.0001
Belt 883 (31.98) 598 (29.66) 285 (38.26) 579 (33.05) 304 (30.13) < 0.0001
Buckle 612 (22.17) 452 (22.42) 160 (21.48) 423 (24.14) 189 (18.73)
Non-Belt 1266 (45.85) 966 (47.92) 300 (40.27) 750 (42.81) 516 (51.14)
CKD Stage 4 d 183 (6.63) 109 (5.41) 74 (9.93) < 0.0001 89 (5.08) 94 (9.32) < 0.0001
Smoking Status < 0.0001 0.0013
Current 305 (11.07) 191 (9.49) 114 (15.34) 181 (10.34) 124 (12.33)
Never 1267 (45.97) 921 (45.75) 346 (46.57) 772 (44.11) 495 (49.2)
Former 1184 (42.96) 901 (44.76) 283 (38.09) 797 (45.54) 387 (38.47)
BMI (kg/m2) 0.0007 < 0.0001
Underweight (<18.5) 32 (1.17) 24 (1.2) 8 (1.09) 24 (1.38) 8 (0.8)
Normal (18.5-24.9) 601 (21.98) 454 (22.72) 147 (19.97) 436 (25.13) 165 (16.52)
Overweight (25–29.9) 972 (35.55) 742 (37.14) 230 (31.25) 657 (37.87) 315 (31.53)
Obese (>30) 1129 (41.29) 778 (38.94) 351 (47.69) 618 (35.62) 511 (51.15)
Heart Disease 848 (31.43) 602 (30.57) 246 (33.74) 0.12 590 (34.32) 258 (26.35) < 0.0001
Diabetes 1023 (37.17) 683 (34) 340 (45.76) < 0.0001 536 (30.7) 487 (48.41) < 0.0001
Hypertension 2315 (84.27) 1655 (82.58) 660 (88.83) < 0.0001 1384 (79.4) 931 (92.73) < 0.0001
Gini Indexe 0.003 < 0.0001
<0.442 682 (24.74) 523 (25.98) 159 (21.37) 550 (31.45) 132 (13.1)
0.442-0.463 674 (24.45) 510 (25.34) 164 (22.04) 469 (26.82) 205 (20.34)
0.464-0.486 678 (24.59) 480 (23.85) 198 (26.61) 390 (22.3) 288 (28.57)
>0.486 723 (26.22) 500 (24.84) 223 (29.97) 340 (19.44) 383 (38)
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Table 1 Individual and area level characteristics by individual level income and race, n = 2,761a (Continued)
County Poverty < 0.0001 < 0.0001
<13.41% 692 (25.1) 559 (27.77) 133 (17.88) 532 (30.42) 160 (15.87)
13.41-16.24% 690 (25.03) 508 (25.24) 182 (24.46) 406 (23.21) 284 (28.17)
16.24-19.96% 681 (24.7) 490 (24.34) 191 (25.67) 419 (23.96) 262 (25.99)
>19.96% 694 (25.17) 456 (22.65) 238 (31.99) 392 (22.41) 302 (29.96)
aParticipants with missing data items are not included in the percentages. 3 participants were missing data on education, 5 participants were missing data
smoking status, 27 participants were missing data on BMI, 63 participants were missing data on heart disease, 9 participants were missing data on diabetes and
14 participants were missing data on hypertension. 4 participants were missing data on area-level poverty and Gini-Index.
bComparing Low Income versus Medium/High Income. Low income was defined as < $20,000 and medium/high income was defined as ≥ $20,000.
cComparing black versus white.
dCKD stages 3 and 4 were defined as baseline eGFRs 30–59 (mL/min/1.73 m2) and 15–29 (mL/min/1.73 m2), respectively.
eThe Gini Index, a measure of income heterogeneity which ranges from 0 to 1, was considered with 0 indicating perfectly equal income distribution across
households in a county and 1 indicating all county income was held within one household.
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there was no significant statistical interaction between
race and low income status (p-value = 0.448). When the
composite outcome of ESRD or mortality was consid-
ered, hazard ratios for low income were dampened for
both blacks and whites. Among whites, the unadjusted
HR for low income was 1.33 (95% CI 1.08-1.63) and theFigure 1 All cause-mortality among participants with moderate chron
race and income, n=2,761 b. All cause mortality by race, n=2,789.fully adjusted HR was no longer statistically significant
(HR = 1.23, 95% CI 0.88-1.70). For blacks, the unadjusted
HR associated with low income and incident ESRD or
mortality was 1.55 (95% CI 1.27-1.90) and the fully ad-
justed HR was 1.59 (HR = 1.59, 95% CI 1.16-2.18). There
was no significant interaction between race and income
on mortality (p-value = 0.783).ic kidney disease in the REGARDS Study. a. All cause mortality by
Table 2 Unadjusted and adjusted hazard ratio for mortality and 95% CI among participants with CKD in the REGARDS








model 3 + CKD
stage
HR (95% CI)






model 6 + area
level measuresc
HR (95% CI) model





1.00 1.00 1.00 1.00 1.00 1.00 1.00
Lowe 1.58 (1.36-1.83) 1.72 (1.46-2.03) 1.62 (1.38-1.89) 1.53 (1.30-1.79) 1.46 (1.23-1.74) 1.44 (1.22-1.71) 1.58 (1.24-2.00)
Race
White 1.00 1.00 1.00 1.00 1.00 1.00 1.00
Black 1.17 (1.01-1.35) 1.27 (1.09-1.49) 1.23 (1.06-1.43) 1.24 (1.07-1.45) 1.24 (1.05-1.47) 1.24 (1.04-1.47) 1.30 (1.02-1.65)
aSociodemographic characteristics include age, geographic location, education and gender.
bComorbidities include heart disease, hypertension, and diabetes.
cArea Level measures include county poverty and Gini Index. The Gini Index, a measure of income heterogeneity which ranges from 0 to 1, was considered with 0
indicating perfectly equal income distribution across households in a county and 1 indicating all county income was held within one household.
dBlood pressure (BP) included systolic and diastolic blood pressure. Serum albuminuria (g/dL) was considered.
eLow income was defined as < $20,000 and medium/high income was defined as ≥ $20,000.
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Several factors were independently associated with an
increased adjusted hazard of mortality including age,
CKD severity (stage 4 versus stage 3 HR = 2.26, 95% CI
1.80-2.84), current smoking (HR = 2.58, 95% CI 2.02-
3.27) and former smoking (HR = 1.34, 95% CI 1.14-1.59),
as compared to never smoking. The presence of diabetes
(HR = 1.52, 95% CI 1.30-1.79) or heart disease (HR =
1.59, 95% CI 1.36-1.85) was also associated with in-
creased hazard of mortality in fully adjusted models.
Similar associations were observed when incident ESRD
or mortality were considered as an outcome.
Sensitivity analysis
We compared participants with missing eGFR (n =
1,305) with participants with non-missing eGFR in our
study (2,761). The baseline prevalence of heart disease,
diabetes, and hypertension was 18.4%, 27.7%, and 67.8%,Table 3 Unadjusted and adjusted hazard ratio for mortality o
















1.00 1.00 1.00 1.0
Lowe 1.52 (1.32-1.75) 1.62 (1.40-1.88) 1.46 (1.26-1.70) 1.4
Race
White 1.00 1.00 1.00 1.0
Black 1.45 (1.27-1.66) 1.57 (1.37-1.80) 1.52 (1.32-1.75) 1.5
aSociodemographic characteristics include age, geographic location, education and
bComorbidities include heart disease, hypertension, and diabetes.
cArea Level measures include county poverty and Gini Index. The Gini Index, a mea
indicating perfectly equal income distribution across households in a county and 1
dBlood pressure (BP) included systolic and diastolic blood pressure. Serum albumin
eLow income was defined as < $20,000 and medium/high income was defined as ≥respectively. Among those with missing eGFR mortality
by the end of follow-up was lower among those missing
eGFR (19.5%). In a multivariable model examining
demographic factors related to missing eGFR, black race
(OR = 1.73, 95% CI 1.48-2.01) and gender (OR = 1.18,
95% CI 1.01-1.38) were both positively associated with
missing eGFR. Income was not associated with missing
eGFR.
Discussion and conclusions
Among black and white adults with moderate CKD, low
income was associated with greater mortality compared
to medium/higher income. This association was partially
explained by differences in demographic characteristics,
CKD stage and comorbidity; however, even after adjust-
ment for these factors, the relation persisted. Those with
medium income did have an increased hazard of mortal-








model 6 + area
level measuresc
HR (95% CI)
model 7 + BP and
albuminuriad
0 1.00 1.00 1.00
0 (1.20-1.63) 1.29 (1.10-1.50) 1.28 (1.09-1.51) 1.32 (1.06-1.65)
0 1.00 1.00 1.00
5 (1.35-1.79) 1.52 (1.31-1.77) 1.52 (1.30-1.78) 1.63 (1.31-2.01)
gender.
sure of income heterogeneity which ranges from 0 to 1, was considered with 0
indicating all county income was held within one household.
uria (g/dL) was considered.
$20,000.
Table 4 Adjusted hazard ratios and 95% confidence intervals for mortality or ESRD associated with low income by
race/ethnicity among participants with CKD in the REGARDS study, n = 2,761
Model number Variables included Black HR (95% CI) White HR (95% CI) P-value for interaction
of race and income
1 Low income 1.82 (1.44-2.30) 1.38 (1.12-1.70) 0.075
2 +age 1.69 (1.34-2.14) 1.27 (1.03-1.60) 0.095
3 +gender 1.98 (1.55-2.52) 1.55 (1.24-1.93) 0.124
4 +education 2.04 (1.57-2.65) 1.51 (1.20-1.89) 0.135
4 +geographic locationa 2.03 (1.56-2.64) 1.51 (1.21-1.90) 0.161
5 +CKD stage 1.94 (1.49-2.53) 1.46 (1.16-1.83) 0.236
7 +smoking, BMI and comorbidityb 1.62 (1.24-2.13) 1.42 (1.14-1.77) 0.062
8 +county Gini Index score and poverty 1.59 (1.21-2.08) 1.34 (1.06-1.70) 0.448
aGeographic location includes: stroke belt versus non-stroke belt.
bComorbidities include heart disease, hypertension, and diabetes.
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ity than higher income persons, and the consideration of
the combined outcome of incident ESRD or mortality
did not alter these findings.
Increased mortality among low income participants in
our study is likely multi-factorial. Plantinga et al. re-
ported significantly higher disability among lower in-
come individuals with CKD, which may also be related
to inadequate treatment and self-management [27]. Co-
morbid conditions, including diabetes and hypertension,
are also less likely to be properly managed among those
with lower socioeconomic status. For example, in a
study examining blood pressure control among CKD
stage 3 and 4 patients, 55% of those in the lowest in-
come category had uncontrolled blood pressure com-
pared to 44% of those in the highest [28]. In addition to
the role of treatment and management of CKD, poverty
may impact mortality through other, more direct, path-
ways including stress and inflammation [29,30]. These
factors have been shown to be important predictors of
all-cause mortality [30,31].
In fully adjusted models, we found low income black
and white participants had similar risk of mortality, sug-
gesting the impact of household income on mortality is
similar for both race groups. Previous studies have noted
a particularly detrimental effect of low income on blacks
with regards to CKD prevalence and severity. Lower in-
come was associated with increased odds of CKD among
blacks but not whites in an urban population [18] and
lower income was associated with higher albuminuria in a
study of REGARDS participants [4]. In line with a previ-
ous study noting higher mortality among blacks with pre-
dialysis CKD [11], we found the same after adjustment for
important confounders. Mehrotra et al. found a 78% in-
creased risk of mortality among black CKD persons
>65 years of age using a random-sample of National
Health Interview Survey Data. In contrast, Newsome
et al. noted a survival advantage for blacks with moreadvanced CKD (eGFR <44 ml/min per 1.73 m2) and re-
ported a slight survival advantage for whites among par-
ticipants with less severe CKD (eGFR 45–60) when they
examined Medicare patients admitted for acute myocar-
dial infarction. Similarly, Kovesdy et al. found a survival
advantage among blacks as CKD stage progressed among
males in the U.S. Veterans Administration (VA) health
system [6]. Unlike these studies, we observed a survival
advantage for whites compared to blacks with moderate
CKD. These discordant findings could be due to differences
in study populations. The aforementioned studies were
based on inpatient Medicare and male VA patients, respect-
ively, whereas the REGARDS cohort is well-characterized
population-based sample, which is a strength of this study.
In addition to higher mortality among black participants
in our study, progression to ESRD was also higher among
blacks. These findings are consistent with previous studies
indicating faster progression from CKD to ESRD among
blacks compared to whites [32]. CKD can seldom be
reversed; however its progression can be mitigated and
controlled through blood pressure management, phys-
ical activity, dietary interventions and medication [33].
Delivery of such interventions may be less than ad-
equate among black patients with CKD.
Our study had several limitations. Although we accounted
for disease severity at baseline, we were unable to assess
CKD disease management, which may partially account
for survival variations by income level. Furthermore, we
excluded 1,305 participants with missing eGFR measure-
ments. A sensitivity analysis revealed that participants
missing eGFR had higher survival and lower comorbidity
burden than participants included in our study, but were
not significantly different in terms of age. These observa-
tions provide some evidence that those missing eGFR, on
average, may not have had chronic kidney disease at base-
line and were therefore not eligible to be in our study. An
additional limitation of our study was the use of a single
eGFR measurement to define CKD, which is subject to
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an assessment of disease progression. Therefore, we can
only speculate on mechanisms through which low income
and black race impact mortality. Future longitudinal in-
vestigations of SES, race and mortality among persons
with CKD are encouraged to help further elucidate these
relationships. We also used the same eGFR cutpoints to
define CKD for both blacks and whites. However, while, it
has been suggested that different cutpoints should be used
to define CKD for these groups, a recent study supports
the use of the current CKD definition and staging for both
blacks and whites [34]. We relied on self-reported house-
hold income, which has not been validated and is likely to
be misclassified as participants may overestimate their in-
come. However, misclassification of income may have
been mitigated by having participants select their income
from four categories in the telephone interview compared
to an open-ended question. Additionally, we did not have
information on household size. The average household
size in the US was approximately 2.6 persons in 2010,
which varied greatly among younger age groups [35].
Given the relatively older age in our study there may be
limited variability in household size. Although several
measures of SES were included in our analyses, we did
not have information on utilization of safety net programs
or community health centers among the uninsured which
has been shown to be associated with higher quality of
care for chronic diseases [36].
The limitations of our study are balanced by it being
one of the first to examine the relation of income, race
and mortality in a population-based study of men and
women with CKD. We have shown that income is an
important predictor of mortality for both blacks and
whites with CKD and blacks have higher mortality even
after adjusting for important socio-demographic and
clinical factors. The reasons for such disparities are likely
multifactorial and future longitudinal investigations of
SES, race and mortality among persons with CKD are
warranted.Competing interests
Additional funding was provided by an investigator-initiated grant-in-aid
from Amgen Corporation. Amgen did not have any role in the design and
conduct of the study, the collection, management, analysis, and interpretation
of the data, or the preparation or approval of the manuscript. The manuscript
was sent to Amgen for review prior to submission for publication.
Ms. Fedewa is supported by Emory University’s Laney Graduate School and
Department of Epidemiology. Dr. Crews was supported by the Harold Amos
Medical Faculty Development Program of the Robert Wood Johnson Foundation,
Princeton, NJ and grant 1K23DK097184-01 from the National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK), Bethesda, MD.Authors’ contributions
DC, WM, and SF conceived of the study, and participated in its design of the
study. All authors helped to draft the manuscript. SF performed the statistical
analyses. All authors read and approved the final manuscript.Acknowledgements
This research project is supported by a cooperative agreement U01
NS041588 from the National Institute of Neurological Disorders and Stroke,
National Institutes of Health, Department of Health and Human Services. The
authors thank the investigators, staff, and participants of the REGARDS study
for their valuable contributions. A full list of participating REGARDS
investigators and institutions can be found at http://www.regardsstudy.org.
Author details
1Department of Epidemiology, Emory University, Claudia Nance Rollins
Building, 3rd Floor, 1518 Clifton Road, NE, Atlanta, GA 30322, USA.
2Department of Medicine, Emory University, Atlanta, GA, USA. 3Department
of Epidemiology, University of Alabama at Birmingham, Birmingham, AL,
USA. 4Department of Medicine and Division of Nephrology, University of
Alabama Birmingham, Birmingham, AL, USA. 5Division of Nephrology,
Department of Medicine, Johns Hopkins University, Baltimore, MD, USA.
6Welch Center for Prevention, Epidemiology and Clinical Research, Johns
Hopkins Medical Institutions, Baltimore, MD, USA.
Received: 10 May 2014 Accepted: 13 August 2014
Published: 23 August 2014
References
1. United states renal data systems annual report. [http://www.usrds.org/
2012/slides/indiv/v1index.html]
2. McClellan WM, Newsome BB, McClure LA, Howard G, Volkova N, Audhya P,
Warnock DG: Poverty and racial disparities in kidney disease: the
REGARDS study. Am J Nephrol 2010, 32(1):38–46.
3. McClellan WM, Warnock DG, Judd S, Muntner P, Kewalramani R, Cushman M,
McClure LA, Newsome BB, Howard G: Albuminuria and racial disparities in
the risk for ESRD. J Am Soc Nephrol 2011, 22(9):1721–1728.
4. Crews DC, McClellan WM, Shoham DA, Gao L, Warnock DG, Judd S,
Muntner P, Miller ER, Powe NR: Low income and albuminuria among
REGARDS (Reasons for Geographic and Racial Differences in Stroke)
study participants. Am J Kidney Dis 2012, 60(5):779–786.
5. Kimmel PL, Fwu CW, Eggers PW: Segregation, income disparities, and
survival in hemodialysis patients. J Am Soc Nephrol 2013, 24(2):293–301.
6. Kovesdy CP, Quarles LD, Lott EH, Lu JL, Ma JZ, Molnar MZ, Kalantar-Zadeh K:
Survival advantage in black versus white Men with CKD: effect of
estimated GFR and case Mix. Am J Kidney Dis 2013, 62(2):228–235.
7. Kucirka LM, Grams ME, Lessler J, Hall EC, James N, Massie AB, Montgomery
RA, Segev DL: Association of race and age with survival among patients
undergoing dialysis. JAMA 2011, 306(6):620–626.
8. Owen WF Jr, Chertow GM, Lazarus JM, Lowrie EG: Dose of hemodialysis
and survival: differences by race and sex. JAMA 1998, 280(20):1764–1768.
9. Robinson BM, Joffe MM, Pisoni RL, Port FK, Feldman HI: Revisiting survival
differences by race and ethnicity among hemodialysis patients: the
dialysis outcomes and practice patterns study. J Am Soc Nephrol 2006,
17(10):2910–2918.
10. Crews DC, Sozio SM, Liu Y, Coresh J, Powe NR: Inflammation and the
paradox of racial differences in dialysis survival. J Am Soc Nephrol 2011,
22(12):2279–2286.
11. Mehrotra R, Kermah D, Fried L, Adler S, Norris K: Racial differences in
mortality among those with CKD. J Am Soc Nephrol 2008, 19(7):1403–1410.
12. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem
DN, Levey AS, Sarnak MJ: Chronic kidney disease as a risk factor for
cardiovascular disease and all-cause mortality: a pooled analysis of
community-based studies. J Am Soc Nephrol 2004, 15(5):1307–1315.
13. Smith GL, Shlipak MG, Havranek EP, Masoudi FA, McClellan WM, Foody JM,
Rathore SS, Krumholz HM: Race and renal impairment in heart failure:
mortality in blacks versus whites. Circulation 2005, 111(10):1270–1277.
14. Newsome BB, McClellan WM, Coffey CS, Allison JJ, Kiefe CI, Warnock DG:
Survival advantage of black patients with kidney disease after acute
myocardial infarction. Clin J Am Soc Nephrol 2006, 1(5):993–999.
15. Kovesdy CP, Anderson JE, Derose SF, Kalantar-Zadeh K: Outcomes associated
with race in males with nondialysis-dependent chronic kidney disease.
Clin J Am Soc Nephrol 2009, 4(5):973–978.
16. Merkin SS, Diez Roux AV, Coresh J, Fried LF, Jackson SA, Powe NR:
Individual and neighborhood socioeconomic status and progressive
chronic kidney disease in an elderly population: the Cardiovascular
Health Study. Soc Sci Med 2007, 65(4):809–821.
Fedewa et al. BMC Nephrology 2014, 15:136 Page 9 of 9
http://www.biomedcentral.com/1471-2369/15/13617. Young BA: The interaction of race, poverty, and CKD. Am J Kidney Dis
2010, 55(6):977–980.
18. Crews DC, Charles RF, Evans MK, Zonderman AB, Powe NR: Poverty, race,
and CKD in a racially and socioeconomically diverse urban population.
Am J Kidney Dis 2010, 55(6):992–1000.
19. Bruce MA, Beech BM, Crook ED, Sims M, Wyatt SB, Flessner MF, Taylor HA,
Williams DR, Akylbekova EL, Ikizler TA: Association of socioeconomic status
and CKD among African Americans: the Jackson Heart Study. Am J
Kidney Dis 2010, 55(6):1001–1008.
20. Howard VJ, Cushman M, Pulley L, Gomez CR, Go RC, Prineas RJ, Graham A,
Moy CS, Howard G: The reasons for geographic and racial differences in
stroke study: objectives and design. Neuroepidemiology 2005,
25(3):135–143.
21. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI,
Kusek JW, Eggers P, VanLente F, Greene T, Coresh J: A new equation to
estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604–612.
22. About USRDS. [http://www.usrds.org/]
23. US department of health and human services. The 2005 HHS poverty
guidelines. [http://aspe.hhs.gov/poverty/05poverty.shtml]
24. Patzer RE, McClellan WM: Influence of race, ethnicity and socioeconomic
status on kidney disease. Nat Rev Nephrol 2012, 8(9):533–541.
25. Kramer MR, Hogue CR: Is segregation bad for your health? Epidemiol Rev
2009, 31:178–194.
26. National kidney foundation kidney disease outcomes quality initiative.
[http://www.kidney.org/professionals/kdoqi/guidelines_ckd/p4_class_g2.htm]
27. Plantinga LC, Johansen KL, Schillinger D, Powe NR: Lower socioeconomic
status and disability among US adults with chronic kidney disease,
1999–2008. Prev Chronic Dis 2012, 9:E12.
28. Plantinga LC, Miller ER 3rd, Stevens LA, Saran R, Messer K, Flowers N, Geiss L,
Powe NR: Blood pressure control among persons without and with
chronic kidney disease: US trends and risk factors 1999–2006.
Hypertension 2009, 54(1):47–56.
29. Ranjit N, Diez-Roux AV, Shea S, Cushman M, Ni H, Seeman T: Socioeconomic
position, race/ethnicity, and inflammation in the multi-ethnic study of
atherosclerosis. Circulation 2007, 116(21):2383–2390.
30. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen J:
Socioeconomic factors, health behaviors, and mortality: results from a
nationally representative prospective study of US adults. JAMA 1998,
279(21):1703–1708.
31. Kabagambe EK, Judd SE, Howard VJ, Zakai NA, Jenny NS, Hsieh M, Warnock
DG, Cushman M: Inflammation biomarkers and risk of all-cause mortality
in the reasons for geographic and racial differences in stroke cohort.
Am J Epidemiol 2011, 174(3):284–292.
32. Hsu CY, Lin F, Vittinghoff E, Shlipak MG: Racial differences in the
progression from chronic renal insufficiency to end-stage renal disease
in the United States. J Am Soc Nephrol 2003, 14(11):2902–2907.
33. McClellan WM, Ramirez SP, Jurkovitz C: Screening for chronic kidney
disease: unresolved issues. J Am Soc Nephrol 2003, 14(7 Suppl 2):S81–S87.
34. Wen CP, Matsushita K, Coresh J, Iseki K, Islam M, Katz R, McClellan W, Peralta
CA, Wang H, De Zeeuw D, Astor BC, Gansevoort RT, Levey AS, Levin A:
Relative risks of chronic kidney disease for mortality and end-stage renal
disease across races are similar. Kidney Int 2014.
35. Lofquist D, Lugaila T, O’Connell M, Feliz S: Households and Families: 2010
Census Briefs. In vol. 2013: US Census Bureau; 2012.
36. Hicks LS, O’Malley AJ, Lieu TA, Keegan T, Cook NL, McNeil BJ, Landon BE,
Guadagnoli E: The quality of chronic disease care in U.S. community
health centers. Health Aff (Millwood) 2006, 25(6):1712–1723.
doi:10.1186/1471-2369-15-136
Cite this article as: Fedewa et al.: The association between race and
income on risk of mortality in patients with moderate chronic kidney
disease. BMC Nephrology 2014 15:136.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
